R J Jones

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Cancer stem cells: are we missing the target?
    Richard J Jones
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Natl Cancer Inst 96:583-5. 2004
  2. ncbi HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:641-50. 2008
  3. ncbi Circulating clonotypic B cells in classic Hodgkin lymphoma
    Richard J Jones
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Blood 113:5920-6. 2009
  4. ncbi Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats
    Allison C Sharrow
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Ovarian Res 3:9. 2010
  5. ncbi Stem cells
    Richard Jones
    Johns Hopkins University, Baltimore, Maryland 21218, USA
    Biol Blood Marrow Transplant 16:S115-8. 2010
  6. ncbi Cancer stem cells-clinical relevance
    Richard J Jones
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Room 244, Bunting Blaustein Cancer Research Building, 1650 Orleans St, Baltimore, MD 21231, USA
    J Mol Med (Berl) 87:1105-10. 2009
  7. ncbi Strategies to eliminate cancer stem cells
    R J Jones
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, Room 244, 1650 Orleans St, 21231 Baltimore, USA
    Ernst Schering Found Symp Proc 5:219-30. 2006
  8. ncbi Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma
    Y L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Ann Oncol 21:1203-10. 2010
  9. ncbi Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia
    R A Brodsky
    Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Room 242, 1650 Orleans Street, Baltimore MD 21231, USA
    Ann Intern Med 135:477-83. 2001
  10. ncbi Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes
    Erica D Warlick
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States
    Leuk Res 32:1439-47. 2008

Research Grants

  1. Translational Research in Blood & Marrow Transplantation
    Richard Jones; Fiscal Year: 2007

Detail Information

Publications83

  1. ncbi Cancer stem cells: are we missing the target?
    Richard J Jones
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Natl Cancer Inst 96:583-5. 2004
  2. ncbi HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:641-50. 2008
    ..02). Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD...
  3. ncbi Circulating clonotypic B cells in classic Hodgkin lymphoma
    Richard J Jones
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Blood 113:5920-6. 2009
    ..Although the clinical significance of circulating clonotypic B cells in HL remains unclear, these data suggest they may be the initiating cells for HL...
  4. ncbi Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats
    Allison C Sharrow
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Ovarian Res 3:9. 2010
    ..Limited progress has been made toward improving the survival rate of patients with this disease in part because of the lack of a good animal model. We present here a model of spontaneous ovarian carcinoma arising in a normal Lewis rat...
  5. ncbi Stem cells
    Richard Jones
    Johns Hopkins University, Baltimore, Maryland 21218, USA
    Biol Blood Marrow Transplant 16:S115-8. 2010
    ..This session focuses on different aspects of stem cells from embryonic stem cells to adult stem cells and the biology and therapeutic impact of cancer stem cells...
  6. ncbi Cancer stem cells-clinical relevance
    Richard J Jones
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Room 244, Bunting Blaustein Cancer Research Building, 1650 Orleans St, Baltimore, MD 21231, USA
    J Mol Med (Berl) 87:1105-10. 2009
    ..Better understanding of the biology of CSC, as well as reexamining both our preclinical and clinical drug development paradigms to include the CSC concept, has the potential to revolutionize the treatment of many cancers...
  7. ncbi Strategies to eliminate cancer stem cells
    R J Jones
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, Room 244, 1650 Orleans St, 21231 Baltimore, USA
    Ernst Schering Found Symp Proc 5:219-30. 2006
    ....
  8. ncbi Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma
    Y L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Ann Oncol 21:1203-10. 2010
    ..Rituximab may improve transplant outcomes but may delay immunologic recovery...
  9. ncbi Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia
    R A Brodsky
    Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Room 242, 1650 Orleans Street, Baltimore MD 21231, USA
    Ann Intern Med 135:477-83. 2001
    ..A small pilot study demonstrated that high-dose cyclophosphamide therapy without bone marrow transplantation leads to durable, treatment-free complete remission...
  10. ncbi Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes
    Erica D Warlick
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States
    Leuk Res 32:1439-47. 2008
    ..These results suggest that it is possible to maintain treatment intensity while minimizing toxicity in older, high-risk MDS patients...
  11. ncbi The role of growth factors in the activity of pharmacological differentiation agents
    William H Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cell Growth Differ 13:275-83. 2002
    ..These data suggest that many pharmacological differentiating agents require both cell cycle arrest and lineage-specific growth factors for full activity and may explain why these agents have demonstrated only limited clinical efficacy...
  12. ncbi Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases
    R A Brodsky
    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 2196, USA
    Bone Marrow Transplant 42:523-7. 2008
    ..Nonmyeloablative, HLA-haploidentical BMT with post-transplant CY is a promising approach for patients with life-threatening nonmalignant hematologic disease who lack an HLA-matched sibling donor...
  13. ncbi High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 11:93-100. 2005
    ..These data suggest that patients with lymphomatous involvement of the CNS who achieve CNS remission should be offered BMT if it is otherwise indicated...
  14. ncbi Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide
    L Luznik
    Bone Marrow Transplantation Program, The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 8:377-86. 2002
    ..Clinically significant antitumor responses occur, even among patients who reject their donor grafts...
  15. ncbi Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors
    Greg R Angstreich
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, MD, USA
    Br J Haematol 130:373-81. 2005
    ..At least part of the clinical effect of IFN in CML appears to result from its ability to differentiate primitive CML progenitors...
  16. ncbi Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant
    Greg R Angstreich
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 207, Baltimore, MD 21231, USA
    Curr Opin Oncol 16:95-9. 2004
    ..The impacts of both are in part limited because of their toxicity profiles. Ongoing laboratory investigations and clinical trials remain paramount to providing the best treatment approach for our patients with chronic myeloid leukemia...
  17. ncbi High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus
    Michelle Petri
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Arthritis Rheum 48:166-73. 2003
    ..CONCLUSION: High-dose cyclophosphamide without stem cell transplantation leads to rapid hematopoietic reconstitution and has significant clinical benefit in patients with refractory SLE. Therefore, this approach deserves further study...
  18. ncbi Treatment of hepatitis-associated aplastic anemia with high-dose cyclophosphamide
    William J Savage
    Department of Pediatric Oncology, Johns Hopkins Hospital, Baltimore, Maryland, USA
    Pediatr Blood Cancer 49:947-51. 2007
    ..Demonstrate that high-dose cyclophosphamide (CY) is effective therapy for hepatitis-associated aplastic anemia (HAA)...
  19. ncbi Elimination of alloantibodies by immunoablative high-dose cyclophosphamide
    R A Brodsky
    Johns Hopkins Oncology Center, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Transplantation 71:482-4. 2001
    ..We now examine the ability of high-dose cyclophosphamide to eliminate alloreactivity...
  20. ncbi Hematopoietic stem cell transplantation for systemic lupus erythematosus
    R A Brodsky
    Division of Immunology and Hematopoiesis, Johns Hopkins Oncology Center, Baltimore, Maryland, USA
    Rheum Dis Clin North Am 26:377-87, viii. 2000
    ..Early results employing immunoablative therapy, with or without stem cell rescue, are encouraging; however, longer follow-up and additional patients are necessary to validate this approach...
  21. ncbi Polyomavirus BK infection in blood and marrow transplant recipients
    L K Dropulic
    Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    Bone Marrow Transplant 41:11-8. 2008
    ....
  22. ncbi Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes
    W H Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leukemia 20:458-62. 2006
    ..Quantification of marrow CD34+ cells may serve as an important tool for distinguishing between AA and hMDS...
  23. ncbi Riddle: what do aplastic anemia, acute promyelocytic leukemia, and chronic myeloid leukemia have in common?
    R A Brodsky
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Leukemia 18:1740-2. 2004
    ....
  24. ncbi Long-term results of blood and marrow transplantation for Hodgkin's lymphoma
    G Akpek
    Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    J Clin Oncol 19:4314-21. 2001
    ..CONCLUSION: There seems to be a clinical graft-versus-HL effect associated with allo BMT. Allo BMT for HL also seems to have a lower risk of secondary AML/MDS than auto BMT. Thus, allo BMT warrants continued study in HL...
  25. ncbi Characterization of chronic myeloid leukemia stem cells
    Jonathan M Gerber
    Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Am J Hematol 86:31-7. 2011
    ..These expression patterns suggest that PROTEINASE 3, SURVIVIN, and hTERT are not optimal therapeutic targets in CML stem cells; whereas PRAME and WT1 seem promising...
  26. ncbi Use of T-cell antibodies for donor dosaging in a canine model of in utero hematopoietic stem cell transplantation
    Scott M Petersen
    Department of Gynecology and Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Fetal Diagn Ther 22:175-9. 2007
    ..Microchimerism following canine in utero hematopoietic stem cell transplantation (IUHSCT) development of T-cell dosing regimens...
  27. ncbi High-dose cyclophosphamide for graft-versus-host disease prevention
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Curr Opin Hematol 17:493-9. 2010
    ..This strategy has recently been adapted to human transplantation...
  28. ncbi Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 13:4467-73. 2007
    ..We have now completed a phase II study of sequential flavopiridol, ara-C, and mitoxantrone in 62 adults with poor-risk AML...
  29. ncbi Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma
    Javier Bolaños-Meade
    George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 13:1185-91. 2007
    ..The administration of oral cyclosporine followed by interleukin-2 and gamma-interferon is generally not well tolerated, and does not appear to be an effective method to induce autologous GVHD in patients receiving autologous PBSC grafts...
  30. ncbi Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas
    Yvette L Kasamon
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 17:365-73. 2011
    ..Thus, 4-HC-purged ABMT can produce extended remissions in a subgroup of patients with indolent lymphomas...
  31. ncbi Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF
    B Douglas Smith
    Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Leuk Res 35:87-94. 2011
    ..We developed a dose finding trial to assess toxicity, differentiating activity, and clinical impact of the combination of bryostatin-1 and GM-CSF...
  32. ncbi High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial
    Michelle Petri
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Arthritis Rheum 62:1487-93. 2010
    ..We undertook this study to compare the efficacy and safety of the standard regimen versus a high-dose IV cyclophosphamide regimen...
  33. ncbi High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 115:3224-30. 2010
    ..These results suggest that high-dose posttransplantation cyclophosphamide is an effective single-agent prophylaxis of acute and chronic GVHD after BuCy conditioning and HLA-matched BMT (clinicaltrials.gov no. NCT00134017)...
  34. ncbi Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 68:190-7. 2008
    ..Our results suggest that circulating clonotypic B-cell populations represent multiple myeloma stem cells, and the relative drug resistance of these cells is mediated by processes that protect normal stem cells from toxic injury...
  35. ncbi High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up
    Robert A Brodsky
    Division of Hematology, Department of Medicine, Johns Hopkins University School ofMedicine, 720 Rutland Ave, Ross Bldg, Rm 1025, Baltimore, MD 21205, USA
    Blood 115:2136-41. 2010
    ....
  36. ncbi Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Leuk Res 34:877-82. 2010
    ..Short OS and DFS correlated with adverse cytogenetics, regardless of age or treatment in CR. The addition of allogeneic BMT in CR translates into long OS and DFS in the majority of eligible patients...
  37. ncbi Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome
    Yvette L Kasamon
    Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 16:482-9. 2010
    ..55, P = .03 for 3-4 vs fewer allele mismatches). Thus, greater HLA disparity does not appear to worsen overall outcome after NMA haploidentical BMT with high-dose posttransplantation cyclophosphamide...
  38. ncbi Cyclophosphamide and cancer: golden anniversary
    Ashkan Emadi
    Division of Adult Hematology, Johns Hopkins University, Baltimore, MD, USA
    Nat Rev Clin Oncol 6:638-47. 2009
    ..We also discuss the development of high-dose cyclophosphamide for BMT and the treatment of autoimmune diseases...
  39. ncbi Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantages
    Robert A Brodsky
    The Division of Hematology, Johns Hopkins University School of Medicine, Ross Research Building, Baltimore, MD 21205, USA
    Autoimmunity 41:596-600. 2008
    ....
  40. ncbi Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning
    Yvette L Kasamon
    Johns Hopkins University, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 15:242-8. 2009
    ..The favorable outcome achieved here in historically poor-risk patients warrants further, more definitive investigation of treatment modification based on early PET scanning...
  41. ncbi Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation
    Heather J Symons
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 16:533-42. 2010
    ..These findings suggest that selection of donors based upon inhibitory KIR gene or haplotype incompatibility may be warranted...
  42. ncbi Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma
    Ivan Aksentijevich
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 12:965-72. 2006
    ..Auto-BMT and allo-BMT produced similar survival for patients with relapsed DLCL. For patients with sensitive disease, allo-BMT seemed to provide longer survival with less relapse; however, this was achieved at the cost of greater TRM...
  43. ncbi High-dose cyclophosphamide as salvage therapy for severe aplastic anemia
    Robert A Brodsky
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Exp Hematol 32:435-40. 2004
    ..The aim of this study was to evaluate high-dose cyclophosphamide in patients with refractory severe aplastic anemia (SAA)...
  44. ncbi Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia
    Robert Iannone
    Department of Pediatrics, Johns Hopkins Hospital and Oncology Center, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 9:519-28. 2003
    ....
  45. ncbi Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells
    Carol Ann Huff
    Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Baltimore, MD, USA
    Biol Blood Marrow Transplant 9:312-9. 2003
    ..Unlike chronic myelogenous leukemia, the antimyeloma effect of allogeneic T cells rarely occurs in the absence of clinically significant GVHD...
  46. ncbi Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Br J Haematol 121:251-8. 2003
    ..These results suggest that the differentiating activities of IFN-alpha may play a role in its clinical antimyeloma activity and provide the rationale for clinical differentiation therapy in MM...
  47. ncbi Bone marrow transplantation for multiple myeloma: where we are today
    Carol Ann Huff
    Johns Hopkins University, Department of Oncology, Baltimore, Maryland 21231, USA
    Curr Opin Oncol 14:147-51. 2002
    ....
  48. ncbi Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia
    William Matsui
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Br J Haematol 128:853-62. 2005
    ..The combined use of pharmacologic differentiating agents and growth factors may improve the clinical efficacy of differentiation therapy in APL...
  49. ncbi Aplastic anaemia
    Robert A Brodsky
    Johns Hopkins University School of Medicine, Division of Hematology, and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Lancet 365:1647-56. 2005
    ..Acquired aplastic anaemia can be effectively treated by allogeneic bone-marrow transplantation, immunosuppression (generally antithymocyte globulin and ciclosporin), and high-dose cyclophosphamide...
  50. ncbi The paradox of response and survival in cancer therapeutics
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 107:431-4. 2006
    ..In this article, we discuss the evidence for cancer stem cells in hematologic malignancies and possible ways to begin targeting these cells and measuring clinical effectiveness of such treatment approaches...
  51. ncbi Characterization of clonogenic multiple myeloma cells
    William Matsui
    Sidney Kimmel Comprehensive Cancer Center, John Hopkins University School of Medicine, Bunting Blaustein Cancer Research Bldg, Rm 245, 1650 Orleans St, Baltimore, MD 21231, USA
    Blood 103:2332-6. 2004
    ..These data suggest that MM "stem cells" are CD138- B cells with the ability to replicate and subsequently differentiate into malignant CD138+ plasma cells...
  52. ncbi Strategies to eliminate cancer stem cells: clinical implications
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231, USA
    Eur J Cancer 42:1293-7. 2006
    ..Re-examining both our pre-clinical and clinical drug development paradigms to include the cancer stem cell concept has the potential to revolutionize the treatment of many cancers...
  53. ncbi Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience
    B Douglas Smith
    Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Rm 246, 1650 Orleans Street, Baltimore, MD 21231, USA
    Br J Haematol 117:907-13. 2002
    ..4HC-purged autologous BMT produced results similar to allogeneic BMT for AML patients beyond first remission...
  54. ncbi Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 12:414-21. 2006
    ..However, with the exception of CML, most patients die of their underlying disease because of insufficient antitumor activity even with active GVHD...
  55. ncbi High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias
    S Morisot
    Department of Pediatrics, Center for Stem Cell Biology and Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Leukemia 24:1859-66. 2010
    ..This very high frequency of LSCs suggests that a hierarchical LSC model is not valuable for poor-outcome ALL...
  56. ncbi Cancer stem cells in hematopoietic malignancies
    Richard J Jones
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:12-6. 2008
    ..A detailed understanding of these processes could lead to development of therapeutics that more effectively treat hematopoietic malignancies and potentially other cancers...
  57. ncbi Association of Foxp3 regulatory gene expression with graft-versus-host disease
    Yuji Miura
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Blood 104:2187-93. 2004
    ..The decrease in regulatory mechanisms after transplantation appears to provide an environment permissive to the development of GVHD...
  58. ncbi Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 11:39-46. 2005
    ..Whether allogeneic BMT ultimately confers an advantage because of a graft-versus-lymphoma effect remains to be determined...
  59. ncbi Phase I study of escalating doses of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients with chemotherapy-resistant non-Hodgkin's or Hodgkin's lymphoma
    D Y Song
    Division of Radiation Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    Int J Radiat Oncol Biol Phys 57:166-71. 2003
    ..This regimen safely permits the use of a total combined radiation dose of up to 2700 cGy during 2 weeks, with encouraging in-field response rates in treatment-refractory patients...
  60. ncbi Bone marrow transplantation in Shwachman-Diamond syndrome
    J W Hsu
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Bone Marrow Transplant 30:255-8. 2002
    ..Although experience is limited, a review of the reported cases suggests patients with SDS may be transplanted without significant short-term morbidity and mortality...
  61. ncbi Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma
    J G Berdeja
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 7:561-7. 2001
    ..Thus, if there is a role for allogeneic BMT in the management of patients with these tumors, it is early in the course of the disease...
  62. ncbi High-dose cyclophosphamide for refractory autoimmune hemolytic anemia
    Victor M Moyo
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 100:704-6. 2002
    ..High-dose cyclophosphamide was well tolerated and induced durable remissions in patients with severe refractory autoimmune hemolytic anemia...
  63. ncbi Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells
    Wen-Chien Chou
    Program of Human Genetics and Molecular Biology, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Proc Natl Acad Sci U S A 101:4578-83. 2004
    ..Our findings pinpoint the arsenic target of ROS production and provide a conceptual basis for an anticancer regimen...
  64. ncbi Integrating PET and PET/CT into the risk-adapted therapy of lymphoma
    Yvette L Kasamon
    Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Nucl Med 48:19S-27S. 2007
    ..We selected aggressive lymphomas as a platform for the discussion of these imaging modalities in oncology patients and the resulting management questions...
  65. ncbi The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia
    C B Miller
    The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Exp Hematol 29:1336-46. 2001
    ..Corresponding probabilities in second remission were 39% (25-53%) and 10% (1-29%). CONCLUSION: Grafts purged with 4HC are associated with higher leukemia-free survival after autologous bone marrow transplants for AML...
  66. ncbi Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia
    G L Mukhina
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
    Br J Haematol 115:476-82. 2001
    ..These studies demonstrate that aerolysin-based assays can reveal previously undetectable multilineage PNH cells in patients with untreated aplastic anaemia. Thus, clonality appears to be an early feature of aplastic anaemia...
  67. ncbi Induction of acute lymphocytic leukemia differentiation by maintenance therapy
    T L Lin
    The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Leukemia 21:1915-20. 2007
    ..These data suggest that induction of leukemia progenitor differentiation plays an important role in the mechanism of action of maintenance therapy in ALL...
  68. ncbi Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen
    J Bolanos-Meade
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Bone Marrow Transplant 43:477-80. 2009
    ..The combination of fludarabine and alemtuzumab is an effective and well-tolerated salvage conditioning regimen for patients who experience graft failure after blood or marrow transplants...
  69. ncbi Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy
    E M Sotomayor
    The Johns Hopkins Oncology Center, 1650 Orleans Street, Baltimore, MD 21231-1000, USA
    Leuk Res 26:461-71. 2002
    ..Autologous BMT was not superior to chemotherapy, and appears unlikely to provide adequate curative treatment for most adult ALL patients if not followed by maintenance...
  70. ncbi Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH
    William J Savage
    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 2196, USA
    Exp Hematol 37:42-51. 2009
    ..Investigate the contribution of PIG-A mutations to clonal expansion in paroxysmal nocturnal hemoglobinuria (PNH)...
  71. ncbi Silencing of genes required for glycosylphosphatidylinositol anchor biosynthesis in Burkitt lymphoma
    Rong Hu
    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 2196, USA
    Exp Hematol 37:423-434.e2. 2009
    ..To investigate the mechanism of glycosylphosphatidylinositol (GPI) anchor deficiency in Burkitt lymphoma cell lines...
  72. ncbi PIG-A mutations in normal hematopoiesis
    Rong Hu
    Johns Hopkins University, School of Medicine, Division of Hematology, Baltimore, MD 21205, USA
    Blood 105:3848-54. 2005
    ..Our data confirm the finding that PIG-A mutations are relatively common in normal hematopoiesis; however, the finding suggests that these mutations occur in differentiated progenitors rather than HSCs...
  73. ncbi Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide
    Daniel B Drachman
    Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    Ann Neurol 53:29-34. 2003
    ..High-dose cyclophosphamide treatment appears to be an effective and safe treatment for selected patients with refractory MG. Further follow-up of these and additional patients will be needed to determine whether the benefit is durable...
  74. ncbi Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes
    Yi Huang
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Clin Cancer Res 15:7217-28. 2009
    ..We hypothesized that a novel class of oligoamine analogues would effectively inhibit LSD1 and thus cause the reexpression of aberrantly silenced genes...
  75. ncbi Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis
    Chitra Krishnan
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287 5371, USA
    Arch Neurol 65:1044-51. 2008
    ..To explore the safety and effectiveness of high-dose cyclophosphamide (HiCy) without bone marrow transplantation in patients with aggressive multiple sclerosis (MS)...
  76. ncbi Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis
    Daniel B Drachman
    Department of Neurology, Johns Hopkins School of Medicine, Meyer Building 5 119, 600 North Wolfe Street, Baltimore, MD 21287 7519, USA
    Ann N Y Acad Sci 1132:305-14. 2008
    ..quot; We therefore recommend that treatment of refractory MG with Hi Cy be followed with maintenance immunotherapy...
  77. ncbi Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support
    Antonio C Wolff
    J Clin Oncol 24:2392-4; author reply 2394-5. 2006
  78. ncbi Epstein-Barr virus lytic infection induces retinoic acid-responsive genes through induction of a retinol-metabolizing enzyme, DHRS9
    Richard J Jones
    Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27514, USA
    J Biol Chem 282:8317-24. 2007
    ..Production of RA during the lytic form of EBV infection may enhance viral replication by promoting keratinocyte differentiation...
  79. ncbi Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease
    Richard J Jones
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Int J Cancer 121:1274-81. 2007
    ..These results suggest that both BRLF1 and BZLF1 contribute to IL-6 secretion in lytically infected cells and that lytically infected cells may promote early lymphoproliferative disease in patients through enhanced IL-6 production...
  80. ncbi Long-term follow-up of allogeneic marrow transplantation for acute myelogenous leukemia after treatment with busulfan and cyclophosphamide
    Javier Bolaños-Meade
    Biol Blood Marrow Transplant 12:366-7. 2006
  81. ncbi High-dose cyclophosphamide in severe aplastic anaemia
    Richard J Jones
    Br J Haematol 125:408-9; author reply 409-10. 2004
  82. ncbi Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma
    Richard J Jones
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 14:5416-25. 2008
    ..The ubiquitin-proteasome pathway has been validated as a target in non-Hodgkin's lymphoma through demonstration of the activity of the proteasome inhibitor bortezomib...
  83. ncbi The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention
    David E Gerber
    Division of Hematology Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, USA
    Blood 112:504-10. 2008
    ..2; 95% CI, 1.4-3.6). In HSCT patients, VTE is primarily catheter-related and 3-fold less common than clinically significant bleeding. These findings warrant consideration when selecting VTE prophylaxis in HSCT patients...

Research Grants3

  1. Translational Research in Blood & Marrow Transplantation
    Richard Jones; Fiscal Year: 2007
    ..End of abstract.) ..